Tag: Xarelto Lawsuit

Can Xarelto Trial Data Be Trusted?

Trepidations have been brought up that a medical device used in Xarelto’s clinical trial was defective, which may have influenced test results as more Xarelto lawsuits are added to the multidistrict litigation. Although Janssen Pharmaceuticals and the study’s authors maintain the study’s conclusions are accurate, their critics demand for an investigation to be done.

ROCKET-AF trial (Rivaroxaban Once Daily Oral Direct Factor XA Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) which was published in 2011 in the New England Journal of Medicine, is the study in question. That study discovered that both rivaroxaban (the generic version of Xarelto) and warfarin – the older-generation anticoagulant – each lessened the risk of systemic embolism or ischemic stroke. The study also found no substantial difference between warfarin and rivaroxaban in the risk of a major bleeding event, but found rivaroxaban was linked with a lower risk of bleeding in the brain and fatal bleeding.

Janssen and Bayer Pharmaceuticals banked only on ROCKET-AF when it applied for approval from the FDA and European regulators according to editors at The BMJ (2/3/16). The study utilised a device known as an INRatio Monitor System, which measures the period it takes for blood to clot and which was recalled in December 2014 due to “clinically considerably lower” test results than patients might see in laboratory testing.

“In terms of the trial results, it could make rivaroxaban seem safer than it was in terms of the risk of bleeding and throws doubt on outcomes used to support the use of the world’s bestselling new oral anticoagulant,” Deborah Cohen writes in The BMJ “A falsely low reading could mean that patients had their warfarin dose unnecessarily increased, leading to a great risk of bleeding.”

Various critics have asked for an independent investigation of the ROCKET-AF trial, to find out whether the results were lopsided by the faulty device. The BMJ claims the FDAhas promised to review relevant data. However, the makers of the recalled device claim their own analysis confirmed the results of the study.

According to reliable reports, the study’s authors studied data and discovered that the likely device’s malfunction “did not have any substantial clinical effect on the major efficacy and safety results in the trial.” The European Medicines Agency is also quoted to have said that the recalled device did not influence the ROCKET-AF trial results.

There were 2,826 lawsuits consolidated for pretrial proceedings in MDL-2592, In Re: Xarelto (Rivaroxaban) Products Liability Litigation before US District Judge Eldon E. Fallon as of January 15, 2016.

It's only fair to share...Share on FacebookShare on Google+Tweet about this on TwitterPin on PinterestShare on LinkedInDigg thisShare on TumblrShare on RedditEmail this to someone

Xarelto Lawsuits Are Gaining Momentum by the Day

Xarelto lawsuits alleging patients suffered severe bleeding events after using the anticoagulant drug are gaining momentum, with over 2,000 lawsuits awaiting courts to listen. Accusers claim they were not warned Xarelto had no antidote and were not warned about the risks of a serious bleeding event while using the drug.

As of December 15, 2015, there were 2,400 lawsuits merged for pretrial proceedings in MDL 2592 (In Re: Xarelto (Rivaroxaban) Products Liability Litigation, before US District Judge Eldon E. Fallon) according to reports from the Judicial Panel for Multidistrict Litigation (JPML). While the growth of the MDL has slowed down somewhat from October, there is still a substantial number of lawsuits added to the MDL every month. Up to 2,266 lawsuits were consolidated as of November 16, 2015, which was up from the 1,698 lawsuits consolidated by mid-October.

Lawsuits claims users were not warned that Xarelto, unlike Coumadin, did not contain an antidote to the medication’s anticlotting property. Xarelto is an anticoagulant, used to lessen the risk of blood clots and strokes. However it, like its precursor Coumadin, is related with an augmented risk of serious bleeding events due to its anticlotting mechanism.

Having been in the markets for decades, Coumadin has an antidote in the form of vitamin K. Users who suffered a bleeding event and received medical care in time could end the adverse condition. However, individuals using newer anticoagulants such as Xarelto, presently have no recognized antidote. That means if they suffer a bleeding event, they have to wait for the drug to leave their system. Appellants claim that they wouldn’t have used Xarelto if they had known it didn’t have an antidote.

The first bellwether trials in the Xarelto lawsuit are not expected to go to court until early 2017. In a case management order (11/30/15), Judge Fallon noted that the two sides could not resolve differences regarding discovery pool appellants and bellwether trial appellants, and gave out orders about how cases could be carefully chosen for inclusion in the discovery pool. The judge also noted that four cases will be chosen as bellwether cases but did not issue an order on choosing bellwether trial cases.

Janssen Pharmaceuticals who manufactured Xarelto, maintains the medication is not perversely perilous and the warnings given on the drug usage are sufficient.

It's only fair to share...Share on FacebookShare on Google+Tweet about this on TwitterPin on PinterestShare on LinkedInDigg thisShare on TumblrShare on RedditEmail this to someone